vimarsana.com

Prnewswire Inhibikase Therapeutics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesMilton wernerAlex loboMiltonh wernerInhibikase therapeutics incPrnewswire inhibikase therapeutics incCompany contactSternir incExchange commissionInhibikase or companyAbelson tyrosine kinasesChief executive officerAbelson tyrosine kinaseOrphan drug designationChronic myelogenous leukemiaAbleson tyrosine

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

BOSTON and ATLANTA, Aug. 7, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of.

United statesMiltonh wernerAlex loboInhibikase therapeutics incCompany contactInhibikase or companySternir incPrnewswire inhibikase therapeutics incAbelson tyrosine kinasesAbelson tyrosine kinaseAbleson tyrosineMultiple system atrophy

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase.

United statesAlex loboMiltonh wernerCompany contactInhibikase or companyExchange commissionPrnewswire inhibikase therapeutics incSternir incNasdaq stock marketInhibikase therapeutics incAbelson tyrosine kinasesListing qualifications staffInhibikase therapeuticsNasdaq listing ruleAbelson tyrosine kinaseAbleson tyrosine

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

BOSTON and ATLANTA, July 17, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of.

United statesMiltonh wernerAlex loboPrnewswire inhibikase therapeutics incNasdaq stock marketInhibikase or companyCompany contactSternir incInhibikase therapeutics incExchange commissionAbelson tyrosine kinasesListing qualifications staffInhibikase therapeuticsNasdaq listing ruleAbelson tyrosine kinaseAbleson tyrosine

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

BOSTON and ATLANTA, June 29, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of

United statesMiltonh wernerAlex loboInhibikase or companyAmerican stock transfer trust companyCompany contactSternir incExchange commissionPrnewswire inhibikase therapeutics incInhibikase therapeutics incAbelson tyrosine kinasesNasdaq capital marketAmerican stock transferTrust companyAbelson tyrosine kinaseAbleson tyrosine

vimarsana © 2020. All Rights Reserved.